Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Actavis pl, AstraZeneca deal

    Actavis plc (NYSE:ACT), Dublin, Ireland AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Business: Pulmonary AstraZeneca completed the purchase of U.S. and Canadian rights to Actavis branded respiratory portfolio (see …

    Published on 3/23/2015
  • Allergan, Actavis deal

    Allergan Inc., Irvine, Calif. Actavis plc (NYSE:ACT), Dublin, Ireland Business: Pharmaceuticals Actavis completed its acquisition of Allergan, which will become an indirect subsidiary of Actavis (see BioCentury, Nov. 24…

    Published on 3/23/2015
  • Asklepion Pharmaceuticals, Retrophin deal

    Asklepion Pharmaceuticals LLC, Baltimore, Md. Retrophin Inc. (NASDAQ:RTRX), New York, N.Y. Business: Gastrointestinal Retrophin will acquire Cholbam cholic acid from Asklepion following FDA approval of the product to …

    Published on 3/23/2015
  • Coronado Biosciences Inc, TG Therapeutics deal

    Coronado Biosciences Inc. (NASDAQ:CNDO), Burlington, Mass. TG Therapeutics Inc. (NASDAQ:TGTX), New York, N.Y. Business: Cancer Coronados Checkpoint Therapeutics Inc. subsidiary granted TG Therapeutics exclusive, …

    Published on 3/23/2015
  • Domain Therapeutics, CleveXel Pharma deal

    Domain Therapeutics S.A., Strasbourg, France CleveXel Pharma S.A.S., Maisons-Alfort, France Business: Neurology Domains Kaldi Pharma Special Purpose Vehicle (SPV) granted CleveXel exclusive, worldwide rights to develop …

    Published on 3/23/2015
  • Eli Lilly and Co, Denovo Biopharma deal

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Denovo Biopharma LLC, San Diego, Calif. Business: Neurology Eli Lilly granted Denovo exclusive, worldwide rights to develop and commercialize pomaglumetad (formerly …

    Published on 3/23/2015
  • Ember Therapeutics, Mariel deal

    Ember Therapeutics Inc., Watertown, Mass. Mariel Therapeutics Inc., New York, N.Y. Business: Renal, Endocrine/Metabolic, Inflammation Obesity and diabetes company Ember and Mariel, which is developing compounds …

    Published on 3/23/2015
  • Endo International pl, Boston Scientific deal

    Endo International plc (NASDAQ:ENDP;TSX:ENL), Dublin, Ireland Boston Scientific Corp. (NYSE:BSX), Natick, Mass. Business: Genitourinary, Other Boston Scientific will purchase Endos American Medical Systems (AMS) urology…

    Published on 3/23/2015
  • Evotec A, Sanofi deal

    Evotec AG (Xetra:EVT), Hamburg, Germany Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Business: Cancer Evotec and Sanofi announced several deals covering cancer candidates and services under which Evotec will receive a …

    Published on 3/23/2015
  • Galapagos N.V, J&J deal

    Galapagos N.V. (Euronext:GLPG;Pink:GLPYY), Mechelen, Belgium Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Inflammation Galapagos and Johnson & Johnsons Janssen Pharmaceutica N.V. unit terminated an …

    Published on 3/23/2015
  • Genmab A/, GlaxoSmithKline, Novartis deal

    Genmab A/S (CSE:GEN;OTCBB:GMXAY), Copenhagen, Denmark GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Business: Cancer Genmab completed the transfer of its deal …

    Published on 3/23/2015
  • GlaxoSmithKline pl, Novartis deal

    GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Business: Cancer Novartis completed the acquisition of GlaxoSmithKlines 11 marketed cancer drugs and two …

    Published on 3/23/2015
  • GlaxoSmithKline pl, Novartis deal

    GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Business: Generics, Pharmaceuticals Novartis and GlaxoSmithKline completed the formation of their JV consisting of…

    Published on 3/23/2015
  • GlaxoSmithKline pl, Sun Pharmaceutical deal

    GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Sun Pharmaceutical Industries Ltd. (BSE:524715;NSE:SUNPHARMA), Mumbai, India Business: Neurology An undisclosed Sun Pharmaceutical subsidiary will purchase …

    Published on 3/23/2015
  • Hanmi Pharmaceutical Co. Ltd, Eli Lilly deal

    Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940), Seoul, South Korea Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Autoimmune Hanmi granted Eli Lilly exclusive, worldwide rights to develop and commercialize …

    Published on 3/23/2015
  • Hanmi Pharmaceutical Co. Ltd, Spectrum Pharmaceuticals deal

    Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940), Seoul, South Korea Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI), Henderson, Nev. Business: Cancer Spectrum received exclusive ex-Korean and Chinese rights from Hanmi to …

    Published on 3/23/2015
  • Helmholtz Association, Spero Therapeutics deal

    Helmholtz Association, Berlin, Germany Spero Therapeutics LLC, Cambridge, Mass. Business: Infectious Helmholtz Associations tech transfer partner, Ascenion, granted Spero exclusive rights to develop and commercialize …

    Published on 3/23/2015
  • Illumina Inc, Merck KGaA deal

    Illumina Inc. (NASDAQ:ILMN), San Diego, Calif. Merck KGaA (Xetra:MRK), Darmstadt, Germany Business: Cancer, Pharmacogenetics Illumina partnered with Mercks Merck Serono S.A. unit to develop and commercialize a companion…

    Published on 3/23/2015
  • Innovent Biologics, Eli Lilly deal

    Innovent Biologics Inc., Suzhou, China Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Cancer Eli Lilly and Innovent partnered to develop and commercialize at least three cancer treatments. Lilly is …

    Published on 3/23/2015
  • Isis Pharmaceuticals Inc, GlaxoSmithKline deal

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Business: Endocrine/Metabolic Isis received a $15 million milestone payment from GlaxoSmithKline under an …

    Published on 3/23/2015
  • Novartis A, GlaxoSmithKline deal

    Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Business: Infectious GlaxoSmithKline completed its acquisition of Novartis vaccines business, excluding influenza …

    Published on 3/23/2015
  • PsychoGenics, Resilience Therapeutics deal

    PsychoGenics Inc., Tarrytown, N.Y. Resilience Therapeutics Inc., Boston, Mass. Business: Neurology Resilience and PsychoGenics partnered to discover treatments for post-traumatic stress disorder (PTSD) and related …

    Published on 3/23/2015
  • Salix Pharmaceuticals Ltd, Endo deal

    Salix Pharmaceuticals Ltd. (NASDAQ:SLXP), Raleigh, N.C. Endo International plc (NASDAQ:ENDP;TSX:ENL), Dublin, Ireland Business: Gastrointestinal Endo withdrew its unsolicited offer to acquire Salix for $175 in cash and …

    Published on 3/23/2015
  • Salix Pharmaceuticals Ltd, Valeant Pharmaceuticals deal

    Salix Pharmaceuticals Ltd. (NASDAQ:SLXP), Raleigh, N.C. Valeant Pharmaceuticals International Inc. (TSX:VRX;NYSE:VRX), Laval, Quebec Business: Gastrointestinal Valeant increased its offer to acquire Salix to $173 per …

    Published on 3/23/2015
  • Shin Nippon Biomedical Laboratories Ltd, ISA Pharmaceuticals deal

    Shin Nippon Biomedical Laboratories Ltd. (Tokyo:2395), Tokyo, Japan ISA Pharmaceuticals B.V., Leiden, the Netherlands Business: Cancer, Drug delivery ISA Pharmaceuticals ISA Therapeutics B.V. subsidiary partnered with …

    Published on 3/23/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993